Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer

NCT05245760 is registered in ClinicalTrials.gov with Zhonglin Hao as lead sponsor.

NCT NCT05245760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer
Lead sponsor
Zhonglin Hao
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2022
Completion date
December 31, 2033
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, esophagogastric junction cancer